Table 1.

Characteristics of the 62 URRC patients submitted to HPP/target-therapy or systemic therapy

	All patients (n = 62)	HPP/target-therapy cohort (n = 43)	Systemic therapy cohort (n = 19)	P value (test)
Gender
Male	40	26	14	0.32, ns
Female	22	17	5	(Student t)
Age (years, median/IQR) at the 1st treatment of the 3rd line	62/56–68	60/55–67	65/58–68	0.07, ns, (Mann–Whitney)
Previous treatments of primary tumor
Neo-adjuvant chemo/RT	8	6	2	0.71, ns, (Chi square)
Abdominoperineal resection	32	23	9	0.66, ns, (Chi square)
Low anterior resection	30	20	10	0.66, ns, (Chi square)
Adjuvant chemo/RT	26	19	7	0.59, ns, (Chi square)
Previous treatments of recurrence
Systemic therapy	62	43	19	–
Chemotherapy	62	43	19	–
Fluorouracil	61	43	18	–
Oxaliplatin	61	43	18	–
Irinotecan	62	43	19	–
Capecitabine	10	7	3	1.00, ns, (Fisher exact)
Targeted-therapy	58	40	18	1.00, ns, (Fisher exact)
Cetuximab	18	12	6	0.77, ns, (Fisher exact)
Bevacizumab	52	34	18	0.15, ns, (Fisher exact)
RT	18	14	4	0.54, ns, (Fisher exact)
Surgery	15	13	2	0.12, ns, (Fisher exact)
Yamada’s modified classification (Yamada et al. 2001)
Localizeda	13	9	4	0.88, ns, (Chi square)
Sacral	37	25	12
Lateral	12	9	3
Other metastatic sites
Not	25	19	6	0.35, ns, (Student’t)
Yes	37	24	13
Eastern Cooperative Oncology Group (ECOG)
1	10	7	3	0.88, ns, (Chi square)
2	12	9	3
3	40	27	13
Interval time from URRC diagnosis and the 1st treatment of the 3rd line (months, median/IQR)	14/12–19	15/13–18	14/9–35	0.44, ns, (Mann–Whitney)
Number of cycles of the 3rd line (mean/SD)	2.58/1.10	2.44/1.07	2.89/1.14	0.13, ns, (Student’t)

Chemo/RT systemic chemotherapy/radiotherapy, IQR interquartile range, SD standard deviation, URRC unresectable recurrent rectal cancer, ns not significant

^aThis group included cases with invasion of uterus, vagina, bladder, prostate, seminal vesicles